We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Multiplex Respiratory Panel Integrates Automated Extraction to Streamline High-Volume Testing

By LabMedica International staff writers
Posted on 07 May 2026

Respiratory infections drive heavy testing volumes in clinical laboratories, where accurate, timely results across multiple pathogens are essential. More...

Many labs are seeking to streamline workflows and increase throughput without sacrificing quality. A newly cleared workflow now integrates automated extraction with multiplex respiratory detection to support efficient, high-volume testing.

Applied BioCode’s (Los Angeles, CA, USA) BioCode Respiratory Pathogen Panel (RPP) has received U.S. Food and Drug Administration (FDA) clearance for in vitro diagnostic (IVD) use when paired with nucleic acid extraction on the Thermo Fisher Scientific (Waltham, MA, USA) KingFisher Flex platform. The update adds extraction claims that broaden the RPP workflow options available to clinical laboratories. It is designed to provide greater flexibility in how labs set up and run respiratory testing.

The workflow enables seamless integration of the KingFisher Flex extraction platform with the BioCode MDx-3000 automated detection system. According to the announcement, combining these systems expands the panel’s utility and increases throughput for respiratory testing. Laboratories can streamline operations by pairing the extraction platform and detection system with the RPP, described as an affordable, comprehensive solution for detecting 17 prevalent respiratory pathogens.

The clearance builds on prior FDA authorization of the company’s Gastrointestinal Pathogen Panel with the KingFisher Flex system, reflecting continued validation of flexible, high‑throughput extraction solutions across a multiplexed panel portfolio. The company indicates the new claim is expected to improve workflow efficiency and accelerate delivery of accurate, timely diagnostic results in high‑volume environments.

“Adding the Thermo Fisher KingFisher™ Flex extraction system demonstrates Applied BioCode’s commitment to delivering flexible, high-quality solutions for the molecular diagnostics market,” said Dr. Winston Ho, CEO and founder of the Applied BioCode. “This enhancement reinforces our commitment to enabling accurate and timely respiratory pathogen detection in high-volume testing environments.”

Related Links
Applied BioCode
Thermo Fisher Scientific


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
New
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Multi-Chamber Washer-Disinfector
WD 390
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: New findings demonstrate that anti-Müllerian hormone (AMH) may help identify which breast cancer patients are most likely to benefit from chemotherapy plus endocrine therapy (Image Credit: Shutterstock)

AMH Test Helps Predict Adjuvant Chemotherapy Benefit in Premenopausal Breast Cancer

Hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer can present a difficult treatment decision in premenopausal patients with low recurrence scores.... Read more

Microbiology

view channel
Image: The QIAstat-Dx BCID GPF Plus AMR Panel is the first QIAstat-Dx panel for bloodstream infections to receive FDA clearance (Photo courtesy of Qiagen)

FDA Clears One-Hour Panel for Bloodstream Infection and AMR Detection

Bloodstream infections can rapidly progress to sepsis, a life-threatening condition affecting an estimated 1.7 million adults in the U.S. each year. Rapid identification of pathogens and antimicrobial... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.